Cargando…
SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review
OBJECTIVES: We aimed to review SARS-CoV-2 seroprevalence studies conducted in Europe to understand how they may be used to inform ongoing control strategies for COVID-19. DESIGN: Scoping review of peer-reviewed publications and manuscripts on preprint servers from January 2020 to 15 September 2020....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021754/ https://www.ncbi.nlm.nih.gov/pubmed/33795310 http://dx.doi.org/10.1136/bmjopen-2020-045425 |
_version_ | 1783674798804566016 |
---|---|
author | Grant, Rebecca Dub, Timothée Andrianou, Xanthi Nohynek, Hanna Wilder-Smith, Annelies Pezzotti, Patrizio Fontanet, Arnaud |
author_facet | Grant, Rebecca Dub, Timothée Andrianou, Xanthi Nohynek, Hanna Wilder-Smith, Annelies Pezzotti, Patrizio Fontanet, Arnaud |
author_sort | Grant, Rebecca |
collection | PubMed |
description | OBJECTIVES: We aimed to review SARS-CoV-2 seroprevalence studies conducted in Europe to understand how they may be used to inform ongoing control strategies for COVID-19. DESIGN: Scoping review of peer-reviewed publications and manuscripts on preprint servers from January 2020 to 15 September 2020. PRIMARY MEASURE: Seroprevalence estimate (and lower and upper CIs). For studies conducted across a country or territory, we used the seroprevalence estimate and the upper and lower CIs and compared them to the total number of reported infections to calculate the ratio of reported to expected infections. RESULTS: We identified 23 population-based seroprevalence studies conducted in Europe. Among 12 general population studies, seroprevalence ranged from 0.42% among residual clinical samples in Greece to 13.6% in an area of high transmission in Gangelt, Germany. Of the eight studies in blood donors, seroprevalence ranged from 0.91% in North-Western Germany to 23.3% in a high-transmission area in Lombardy region, Italy. In three studies which recruited individuals through employment, seroprevalence ranged from 0.5% among factory workers in Frankfurt, Germany, to 10.2% among university employees in Milan, Italy. In comparison to nationally reported cases, the extent of infection, as derived from these seroprevalence estimates, is manyfold higher and largely heterogeneous. CONCLUSION: Exposure to the virus in Europe has not reached a level of infection that would prevent further circulation of the virus. Effective vaccine candidates are urgently required to deliver the level of immunity in the population. |
format | Online Article Text |
id | pubmed-8021754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80217542021-04-21 SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review Grant, Rebecca Dub, Timothée Andrianou, Xanthi Nohynek, Hanna Wilder-Smith, Annelies Pezzotti, Patrizio Fontanet, Arnaud BMJ Open Epidemiology OBJECTIVES: We aimed to review SARS-CoV-2 seroprevalence studies conducted in Europe to understand how they may be used to inform ongoing control strategies for COVID-19. DESIGN: Scoping review of peer-reviewed publications and manuscripts on preprint servers from January 2020 to 15 September 2020. PRIMARY MEASURE: Seroprevalence estimate (and lower and upper CIs). For studies conducted across a country or territory, we used the seroprevalence estimate and the upper and lower CIs and compared them to the total number of reported infections to calculate the ratio of reported to expected infections. RESULTS: We identified 23 population-based seroprevalence studies conducted in Europe. Among 12 general population studies, seroprevalence ranged from 0.42% among residual clinical samples in Greece to 13.6% in an area of high transmission in Gangelt, Germany. Of the eight studies in blood donors, seroprevalence ranged from 0.91% in North-Western Germany to 23.3% in a high-transmission area in Lombardy region, Italy. In three studies which recruited individuals through employment, seroprevalence ranged from 0.5% among factory workers in Frankfurt, Germany, to 10.2% among university employees in Milan, Italy. In comparison to nationally reported cases, the extent of infection, as derived from these seroprevalence estimates, is manyfold higher and largely heterogeneous. CONCLUSION: Exposure to the virus in Europe has not reached a level of infection that would prevent further circulation of the virus. Effective vaccine candidates are urgently required to deliver the level of immunity in the population. BMJ Publishing Group 2021-04-01 /pmc/articles/PMC8021754/ /pubmed/33795310 http://dx.doi.org/10.1136/bmjopen-2020-045425 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Epidemiology Grant, Rebecca Dub, Timothée Andrianou, Xanthi Nohynek, Hanna Wilder-Smith, Annelies Pezzotti, Patrizio Fontanet, Arnaud SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review |
title | SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review |
title_full | SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review |
title_fullStr | SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review |
title_full_unstemmed | SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review |
title_short | SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review |
title_sort | sars-cov-2 population-based seroprevalence studies in europe: a scoping review |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021754/ https://www.ncbi.nlm.nih.gov/pubmed/33795310 http://dx.doi.org/10.1136/bmjopen-2020-045425 |
work_keys_str_mv | AT grantrebecca sarscov2populationbasedseroprevalencestudiesineuropeascopingreview AT dubtimothee sarscov2populationbasedseroprevalencestudiesineuropeascopingreview AT andrianouxanthi sarscov2populationbasedseroprevalencestudiesineuropeascopingreview AT nohynekhanna sarscov2populationbasedseroprevalencestudiesineuropeascopingreview AT wildersmithannelies sarscov2populationbasedseroprevalencestudiesineuropeascopingreview AT pezzottipatrizio sarscov2populationbasedseroprevalencestudiesineuropeascopingreview AT fontanetarnaud sarscov2populationbasedseroprevalencestudiesineuropeascopingreview |